Lipid-lowering therapy is effective in reducing cardiovascular mortality and morbidity in people with PAD .
It may also improve local symptoms .
Until further evidence on the relative effectiveness of different lipid-lowering agents is available , use of a statin in people with PAD and a blood cholesterol level > /=3.5 mmol/litre is most indicated
BACKGROUND Lipid-lowering therapy is recommended for secondary prevention in people with coronary artery disease .
It may also reduce cardiovascular events and /or local disease progression in people with lower limb peripheral arterial disease ( PAD ) .
OBJECTIVES To assess the effects of lipid-lowering therapy on all-cause mortality , cardiovascular events and local disease progression in patients with PAD of the lower limb .
Comparison of computer- and human-derived coronary angiographic end-point measures for controlled therapy trials.
The Cholesterol Lowering Atherosclerosis Study , a r and omized angiographic clinical trial , demonstrated the beneficial effect of niacin/colestipol plus diet therapy on coronary atherosclerosis . Outcome was determined by panel-based estimates ( viewed in both still and cine modes ) of percent stenosis severity and change in native artery and bypass graft lesions . Computer-based quantitative coronary angiography ( QCA ) was also used to measure lesion and bypass graft stenosis severity and change in individual frames closely matched in orientation , opacification , and cardiac phase . Both methods jointly evaluated 350 nonoccluded lesions . The correlation between QCA and panel estimates of lesion size was 0.70 ( p less than 0.0001 ) and for change in lesion size was 0.28 ( p = 0.002 ) . Agreement between the two methods in classifying lesion changes ( i.e. , regression , unchanged , or progression ) occurred for 60 % ( 210 of 350 ) of the lesions kappa + /- SEM = 0.20 + /- 0.05 , p less than 0.001 ) . The panel identified 442 nonoccluded lesions for which QCA stenosis measurements could not be obtained . Lesions not measurable by QCA included those with stenosis greater than 85 % that could not be reliably edge tracked , segments with diffuse or ecstatic disease that had no reliable reference diameter , and segments for which matched frames could not be located . Seventy-nine lesions , the majority between 21 % and 40 % stenosis , were identified and measured by QCA but were not identified by the panel . This comparison study demonstrates the need to consider available angiographic measurement methods in relation to the goals of their use
Lipid-lowering therapy is effective in reducing cardiovascular mortality and morbidity in people with PAD .
It may also improve local symptoms .
Until further evidence on the relative effectiveness of different lipid-lowering agents is available , use of a statin in people with PAD and a blood cholesterol level > /=3.5 mmol/litre is most indicated
BACKGROUND Lipid-lowering therapy is recommended for secondary prevention in people with coronary artery disease .
It may also reduce cardiovascular events and /or local disease progression in people with lower limb peripheral arterial disease ( PAD ) .
OBJECTIVES To assess the effects of lipid-lowering therapy on all-cause mortality , cardiovascular events and local disease progression in patients with PAD of the lower limb .